We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Y mAbs Therapeutics Inc | NASDAQ:YMAB | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.59 | -4.58% | 12.28 | 10.90 | 13.57 | 12.96 | 11.91 | 12.96 | 488,643 | 01:00:00 |
From May 2023 to May 2024
By Denny Jacob
Y-mAbs Therapeutics' investigational new drug application for CD38-SADA was cleared by the Food and Drug Administration.
The commercial-stage biopharmaceutical company said CD38-SADA is its second program within its self-assembly disassembly pre-target radioimmunotherapy theranostic platform. The Phase 1 trial is investigating the safety and tolerability of the CD38-SADA: (177) Lu-DOTA Drug Complex in patients with relapsed or refractory non-Hodgkin lymphoma.
Interim Chief Executive Thomas Gad said the FDA's clearance marks the second program utilizing its SADA technology platform to enter clinic development within just 15 months.
Y-mAbs said it expects to dose the first patient in its Phase 1 trial in 2024.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
October 17, 2023 17:46 ET (21:46 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Y mAbs Therapeutics Chart |
1 Month Y mAbs Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
